Quarterly report · Q2
2160.TEDINET S100P1F0
Period2022-01-01 → 2022-06-30
Filed2022-08-15
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.2bn | 2022-01-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.2bn | 2022-04-01 → 2022-06-30d | Cons. | Revenue IFRS |
| Revenue | ¥12.7bn | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥6.5bn | 2021-01-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.6bn | 2021-04-01 → 2021-06-30d | Cons. | Revenue IFRS |
| Operating income | ¥1.0bn | 2022-01-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥526m | 2022-04-01 → 2022-06-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.5bn | 2021-01-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥682m | 2021-04-01 → 2021-06-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥790m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥443m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.2bn | 2021-01-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥522m | 2021-04-01 → 2021-06-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥676m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥325m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥1.1bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥941m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥509m | 2021-04-01 → 2021-06-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥198m | 2022-01-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥126m | 2022-04-01 → 2022-06-30d | Cons. | Profit loss IFRS |
| Net income | ¥55m | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥745m | 2021-01-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥309m | 2021-04-01 → 2021-06-30d | Cons. | Profit loss IFRS |
| Total assets | ¥35.3bn | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥30.3bn | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥29.0bn | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥13.5bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥11.0bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥21.8bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.3bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.1bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥12.8bn | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥22.0bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥18.9bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥17.9bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥14.5bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.4bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.8bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.3bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥389m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥552m | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.5bn | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥261m | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.0bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥267m | 2022-01-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥2.9bn | 2021-01-01 → 2021-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥2.9bn | 2021-01-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥14.25 | 2022-01-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥6.86 | 2022-04-01 → 2022-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥22.72 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥20.3 | 2021-01-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥10.78 | 2021-04-01 → 2021-06-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥14.18 | 2022-01-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥6.83 | 2022-04-01 → 2022-06-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥22.08 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.73 | 2021-01-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥10.59 | 2021-04-01 → 2021-06-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 62.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.3% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.9% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥526m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2022-01-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2022-01-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2022-01-01 → 2022-06-30 | ¥479m |
| —segment total | revenue | 2022-01-01 → 2022-06-30 | ¥8.2bn |
| —segment total | revenue external | 2022-01-01 → 2022-06-30 | ¥8.2bn |
| —segment total | segment profit | 2022-01-01 → 2022-06-30 | ¥1.0bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥1.0bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥1.0bn |
| jpcrp040300-q2r_E05712-000Medical Devicereportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥390m |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue | 2021-01-01 → 2021-06-30 | ¥5.5bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | revenue external | 2021-01-01 → 2021-06-30 | ¥5.5bn |
| jpcrp040300-q2r_E05712-000Pharmaceuticalreportable segment | segment profit | 2021-01-01 → 2021-06-30 | ¥1.1bn |
| —segment total | revenue | 2021-01-01 → 2021-06-30 | ¥6.5bn |
| —segment total | revenue external | 2021-01-01 → 2021-06-30 | ¥6.5bn |
| —segment total | segment profit | 2021-01-01 → 2021-06-30 | ¥1.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 734
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 1165313000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 8154817000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 8154817000 | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | - | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | - | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | - | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Intersegment revenue IFRS | CurrentYTDDuration | - | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 6989504000 | JPY |
| Revenue IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 1165313000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReportableSegmentsMember | 8154817000 | JPY |
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Revenue IFRS | CurrentYTDDuration | 8154817000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000PharmaceuticalReportableSegmentMember | 479123000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E05712-000MedicalDeviceReportableSegmentMember | 525544000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 1004668000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | - | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 1004668000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 175775000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 390055000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 790388000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の4の7第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-08-15 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第22期第2四半期(自 2022年4月1日 至 2022年6月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Company name in english cover page | FilingDateInstant | GNI Group Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役代表執行役社長兼CEO イン・ルオ | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目2番2号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03(6214)3600(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役執行役CFO ジョセフ・フランシス・マイヤー | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目2番2号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03(6214)3600(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役執行役CFO ジョセフ・フランシス・マイヤー | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05712 | |
| Fund code | FilingDateInstant | - | |
| Security code | FilingDateInstant | 21600 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Filer name in english | FilingDateInstant | GNI Group Ltd. | |
| Fund name in japanese | FilingDateInstant | - | |
| Fund name in english | FilingDateInstant | - | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | - |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |